Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer

A. Lipton, S. Scialla, H. Harvey, R. Dixon, R. Gordon, R. Hamilton, H. Ramsey, M. Weltz, R. Heckard, D. White

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Sixty-six patients with Duke's B 2 or C colon or rectal cancer were randomized for treatment with aspirin (ASA), 600 mg, p.o., twice daily x 2 years or placebo (P). Compliance was checked in both groups by random measurement of blood salicylate levels. Fifty-seven patients are currently evaluable. No difference in disease-free (p=.66) or overall survival (p=.90) is present between ASA and P groups. The time at which ASA therapy is started (within 2 or within 4 weeks) following surgery does not affect these results. Aspirin at conventional dosage is ineffective in preventing the appearance of metastases in patients with colo-rectal cancer.

Original languageEnglish (US)
Pages (from-to)419-429
Number of pages11
JournalJournal of Medicine
Volume13
Issue number5-6
StatePublished - Dec 1 1982

Fingerprint

Rectal Neoplasms
Aspirin
Salicylates
Colonic Neoplasms
Compliance
Therapeutics
Placebos
Neoplasm Metastasis
Survival

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lipton, A., Scialla, S., Harvey, H., Dixon, R., Gordon, R., Hamilton, R., ... White, D. (1982). Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. Journal of Medicine, 13(5-6), 419-429.
Lipton, A. ; Scialla, S. ; Harvey, H. ; Dixon, R. ; Gordon, R. ; Hamilton, R. ; Ramsey, H. ; Weltz, M. ; Heckard, R. ; White, D. / Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. In: Journal of Medicine. 1982 ; Vol. 13, No. 5-6. pp. 419-429.
@article{b72599395b42459fa2f07938bb086a63,
title = "Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer",
abstract = "Sixty-six patients with Duke's B 2 or C colon or rectal cancer were randomized for treatment with aspirin (ASA), 600 mg, p.o., twice daily x 2 years or placebo (P). Compliance was checked in both groups by random measurement of blood salicylate levels. Fifty-seven patients are currently evaluable. No difference in disease-free (p=.66) or overall survival (p=.90) is present between ASA and P groups. The time at which ASA therapy is started (within 2 or within 4 weeks) following surgery does not affect these results. Aspirin at conventional dosage is ineffective in preventing the appearance of metastases in patients with colo-rectal cancer.",
author = "A. Lipton and S. Scialla and H. Harvey and R. Dixon and R. Gordon and R. Hamilton and H. Ramsey and M. Weltz and R. Heckard and D. White",
year = "1982",
month = "12",
day = "1",
language = "English (US)",
volume = "13",
pages = "419--429",
journal = "Journal of Medicine",
issn = "0025-7850",
publisher = "S. Karger AG",
number = "5-6",

}

Lipton, A, Scialla, S, Harvey, H, Dixon, R, Gordon, R, Hamilton, R, Ramsey, H, Weltz, M, Heckard, R & White, D 1982, 'Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer', Journal of Medicine, vol. 13, no. 5-6, pp. 419-429.

Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. / Lipton, A.; Scialla, S.; Harvey, H.; Dixon, R.; Gordon, R.; Hamilton, R.; Ramsey, H.; Weltz, M.; Heckard, R.; White, D.

In: Journal of Medicine, Vol. 13, No. 5-6, 01.12.1982, p. 419-429.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer

AU - Lipton, A.

AU - Scialla, S.

AU - Harvey, H.

AU - Dixon, R.

AU - Gordon, R.

AU - Hamilton, R.

AU - Ramsey, H.

AU - Weltz, M.

AU - Heckard, R.

AU - White, D.

PY - 1982/12/1

Y1 - 1982/12/1

N2 - Sixty-six patients with Duke's B 2 or C colon or rectal cancer were randomized for treatment with aspirin (ASA), 600 mg, p.o., twice daily x 2 years or placebo (P). Compliance was checked in both groups by random measurement of blood salicylate levels. Fifty-seven patients are currently evaluable. No difference in disease-free (p=.66) or overall survival (p=.90) is present between ASA and P groups. The time at which ASA therapy is started (within 2 or within 4 weeks) following surgery does not affect these results. Aspirin at conventional dosage is ineffective in preventing the appearance of metastases in patients with colo-rectal cancer.

AB - Sixty-six patients with Duke's B 2 or C colon or rectal cancer were randomized for treatment with aspirin (ASA), 600 mg, p.o., twice daily x 2 years or placebo (P). Compliance was checked in both groups by random measurement of blood salicylate levels. Fifty-seven patients are currently evaluable. No difference in disease-free (p=.66) or overall survival (p=.90) is present between ASA and P groups. The time at which ASA therapy is started (within 2 or within 4 weeks) following surgery does not affect these results. Aspirin at conventional dosage is ineffective in preventing the appearance of metastases in patients with colo-rectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020314785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020314785&partnerID=8YFLogxK

M3 - Article

C2 - 6963332

AN - SCOPUS:0020314785

VL - 13

SP - 419

EP - 429

JO - Journal of Medicine

JF - Journal of Medicine

SN - 0025-7850

IS - 5-6

ER -